APAC IPOs & Placements, Aequitas Research

Hong Jie Seow

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Aequitas: EpiWorld International IPO - Poor Earnings And Premium Val

Aequitas: EpiWorld International PHIP Updates

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Epiworld International / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/epiworld-international-co-ltd" target="_blank" data-smartkarma-citation="entities:47626:1" rel="noopener">EpiWorld International (2726 HK)</a> raised US$209m in its upcoming Hong Kong IPO.</li>
<li>EpiWorld is a global leader in the silicon carbide (SiC) epitaxy industry, according to CIC, and it is primarily engaged in the R&amp;D, production, and sales of SiC epitaxial wafers.</li>
<li>We have covered various aspects of the deal in our previous notes. In this note, we will talk about the demand and trading dynamics.</li>
</ul>



EpiWorld International (2726 HK) raised US$209m in its upcoming Hong Kong IPO.
EpiWorld is a global leader in the silicon carbide (SiC) epitaxy industry, according to CIC, and it is primarily engaged in the R&amp;D, production, and sales of SiC epitaxial wafers.
We have covered various aspects of the deal in our previous notes. In this note, we will talk about the demand and trading dynamics.


Aequitas: EpiWorld Trading - Priced At Mid-Range, Weak Insti Demand